ArticleNature reviews. Rheumatology2021
Spectrum and impact of checkpoint inhibitor-induced irAEs.
Article in Nature reviews. Rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Balancing immunosuppression and cancer survival in the treatment of immune checkpoint inhibitor-associated inflammatory arthritis.EULAR rheumatology open · 2026Review
- Article
- Pretreatment naive T cells are associated with severe irAE following PD-1/CTLA-4 checkpoint blockade for melanoma.JCI insight · 2026Article
- Comprehensive safety analysis of the clinical spectrum of adverse events associated with immune checkpoint inhibitors based on FAERS.Frontiers in immunology · 2026Article
- Review
- Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanoma.bioRxiv : the preprint server for biology · 2025Article
- Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update.Journal for immunotherapy of cancer · 2024Review
- Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus.Frontiers in endocrinology · 2023Article
- Immune-checkpoint inhibitors: long-term implications of toxicity.Nature reviews. Clinical oncology · 2022Review
- Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.Arthritis & rheumatology (Hoboken, N.J.) · 2022Article
- Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33235330What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.